Journal
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
Volume 20, Issue 4, Pages 183-198Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00004850-200507000-00001
Keywords
amisulpride; aripiprazole; atypical antipsychotic agents; clozapine; olanzapine; quetiapine; risperidone; sertindole; ziprasidone
Categories
Ask authors/readers for more resources
This review discusses the atypical antipsychotics, focusing on the possibility of symptom reduction with a minimum of side-effects. A selective review of clinically relevant reports, studies and meta-analyses is presented. The results from clinical trials suggest that atypical agents improve negative and affective symptoms, and cognitive functioning more than typical antipsychotics, but that the pattern of effects on these domains, as well as on suicidality, appears to differ. In clinical trials, the newer drugs generally have less extrapyramidal side-effects (EPS) than typical antipsychotics. However, amisulpride, risperidone, olanzapine and ziprasidone still show evidence of a dose-related increase in EPS, whereas clozapine, quetiapine, sertindole and aripiprazole do not Weight gain, increased blood lipids/ cholesterol, and insulin resistance/type 2 diabetes are emerging as significant treatment-associated concerns, particularly for clozapine and olanzapine. Sedation has been reported for all the newer compounds except sertindole. The considerable variation in benefit/risk profiles of the atypical compounds can help the clinician to select the most appropriate treatment for individual patients. Int Clin Psychopharmacol 20:183-198 (c) 2005 Lippincott Williams & Wilkins.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available